A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray in Healthy Chinese Adult Subjects and Patients With Chronic Rhinosinusitis.
Latest Information Update: 05 Dec 2025
At a glance
- Drugs VVN 432 (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Adverse reactions
- Sponsors VivaVision Biotech
Most Recent Events
- 05 Dec 2025 New trial record